CTOs on the Move

GroupOne Services

www.gp1.com

 
GroupOne Services is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.gp1.com
  • 250 Decker Dr
    Irving, TX USA 75062
  • Phone: 972.719.4208

Executives

Name Title Contact Details

Similar Companies

Registered Practical Nurses Association of Ontario

Registered Practical Nurses Association of Ontario is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Escalon Medical

Escalon Medical Corp. is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diamond Healthcare

Diamond Healthcare Corporation is the national leader in the planning, development and operation of high quality Behavioral Health Services in partnership with healthcare organizations. Diamond`s client relationships span a diverse geographic and demographic range — from rural critical access hospitals to urban academic medical centers, from sole community hospitals to multi-hospital health systems, including faith-based healthcare organizations, not-for-profit systems and for-profit hospital companies. Diamond offers a comprehensive range of healthcare services. 

LifeCenter Northwest

LifeCenter Northwest is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.